Related Experiment Video

Updated: Aug 13, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

The role of protein kinase C-alpha in hematologic malignancies

Michael Lahn1, Karen Sundell, Gabriele Köhler

  • 1Division of Oncology Product Development, Eli Lilly and Company, Indianapolis, IN 46285, USA. mlahn@lilly.com

Acta Haematologica
|January 21, 2006
PubMed

Insights

Targeted cancer therapy is advancing with drugs like aprinocarsen that inhibit protein kinase C-alpha (PKC-alpha). Further understanding PKC-alpha

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Hematologic malignancies are increasingly understood through molecular and histopathological advances.
  • Targeted therapies are emerging, focusing on proteins driving cancer development.
  • Protein kinase C-alpha (PKC-alpha) is implicated in tumorigenesis, but its role in blood cancers is unclear.

Purpose of the Study:

  • To review existing studies on PKC-alpha expression and function in hematologic malignancies.
  • To explore the potential of PKC-alpha as a therapeutic target in these cancers.
  • To inform strategies for patient selection for PKC-alpha inhibiting therapies.

Main Methods:

  • Literature review of studies investigating PKC-alpha.
  • Analysis of PKC-alpha expression patterns in hematologic malignancies.
  • Evaluation of PKC-alpha's role in the development and progression of blood cancers.

Main Results:

  • PKC-alpha is associated with tumorigenesis.
  • Its specific role and expression levels in hematologic malignancies require further elucidation.
  • Targeted inhibition of PKC-alpha is a potential therapeutic strategy.

Conclusions:

  • A comprehensive understanding of PKC-alpha's role is crucial for developing targeted treatments.
  • Identifying patients who would benefit from PKC-alpha inhibition is a key challenge.
  • This review provides insights for future therapeutic strategies in hematologic malignancies.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Related Concept Videos

Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...